Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 16 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-3.58 Insider Own5.81% Shs Outstand208.77M Perf Week98.11%
Market Cap37.22M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float196.63M Perf Month154.71%
Income-41.30M PEG- EPS next Q- Inst Own0.59% Short Float10.02% Perf Quarter87.09%
Sales9.76M P/S3.81 EPS this Y- Inst Trans-2.86% Short Ratio0.35 Perf Half Y-44.28%
Book/sh0.07 P/B2.63 EPS next Y- ROA-84.10% Short Interest19.71M Perf Year-68.99%
Cash/sh0.03 P/C5.75 EPS next 5Y40.00% ROE-1919.14% 52W Range0.05 - 1.22 Perf YTD17.77%
Dividend Est.- P/FCF- EPS past 5Y86.10% ROI-112.11% 52W High-85.39% Beta1.05
Dividend TTM- Quick Ratio1.34 Sales past 5Y39.38% Gross Margin57.87% 52W Low248.24% ATR (14)0.03
Dividend Ex-Date- Current Ratio2.00 EPS Y/Y TTM93.02% Oper. Margin-347.51% RSI (14)74.07 Volatility38.42% 21.23%
Employees49 Debt/Eq7.48 Sales Y/Y TTM-18.36% Profit Margin-423.11% Recom1.00 Target Price6.00
Option/ShortNo / Yes LT Debt/Eq6.43 EPS Q/Q96.34% Payout- Rel Volume13.09 Prev Close0.12
Sales Surprise- EPS Surprise- Sales Q/Q-29.45% EarningsApr 01 BMO Avg Volume55.73M Price0.18
SMA20114.28% SMA50118.84% SMA200-34.75% Trades Volume616,383,616 Change50.08%
Date Action Analyst Rating Change Price Target Change
Jul-07-21Initiated Cantor Fitzgerald Overweight $5
Jul-11-17Initiated Rodman & Renshaw Buy $2
Apr-16-24 11:34AM
Apr-10-24 10:40AM
Apr-09-24 04:15PM
Apr-08-24 08:30AM
11:24AM Loading…
Apr-02-24 11:24AM
Apr-01-24 12:52PM
Mar-27-24 08:30AM
Mar-20-24 08:30AM
Feb-23-24 08:30AM
Feb-15-24 08:30AM
Feb-14-24 08:30AM
08:30AM Loading…
Feb-12-24 08:30AM
Jan-30-24 08:45AM
Jan-29-24 08:30AM
Jan-25-24 08:30AM
Jan-05-24 04:15PM
Jan-04-24 08:30AM
Dec-24-23 05:48PM
Dec-11-23 08:30AM
Dec-07-23 08:30AM
Dec-06-23 08:30AM
Dec-04-23 08:30AM
Nov-30-23 08:30AM
Nov-21-23 08:30AM
Nov-15-23 01:14PM
Nov-14-23 09:00PM
08:00AM Loading…
Nov-10-23 04:15PM
Nov-09-23 08:30AM
Nov-08-23 10:25AM
Nov-07-23 08:30AM
Nov-02-23 08:30AM
Nov-01-23 08:30AM
Oct-31-23 07:00AM
Oct-30-23 08:30AM
Oct-26-23 08:30AM
Oct-25-23 08:00AM
Oct-23-23 08:30AM
Oct-19-23 08:30AM
Oct-18-23 08:30AM
Oct-12-23 08:30AM
Oct-10-23 08:30AM
Sep-28-23 08:30AM
Sep-27-23 08:30AM
Sep-26-23 08:30AM
Sep-21-23 07:30AM
Sep-14-23 08:30AM
Sep-13-23 08:30AM
Sep-12-23 08:30AM
Sep-11-23 08:30AM
Sep-07-23 08:30AM
Sep-05-23 07:00AM
Aug-30-23 08:30AM
Aug-28-23 08:30AM
Aug-24-23 07:00AM
Aug-17-23 08:30AM
Aug-16-23 08:30AM
Aug-14-23 10:16PM
Aug-10-23 08:30AM
Aug-09-23 08:30AM
Aug-08-23 08:30AM
Aug-07-23 08:30AM
Aug-03-23 08:30AM
Aug-02-23 08:30AM
Aug-01-23 08:40AM
Jul-27-23 08:30AM
Jul-26-23 08:30AM
Jul-25-23 08:30AM
Jul-07-23 04:15PM
Jun-28-23 08:30AM
Jun-26-23 08:30AM
Jun-22-23 08:30AM
Jun-20-23 08:30AM
Jun-15-23 08:30AM
Jun-14-23 08:30AM
Jun-13-23 09:55AM
Jun-08-23 03:00PM
Jun-07-23 08:30AM
May-25-23 08:30AM
May-24-23 08:30AM
May-23-23 08:30AM
May-19-23 04:15PM
May-17-23 06:13AM
May-16-23 08:30AM
May-15-23 08:30AM
May-12-23 08:30AM
May-11-23 08:30AM
May-10-23 08:30AM
May-09-23 08:30AM
May-08-23 08:30AM
Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the Human Health and Animal Health segments. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment includes commercializing prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.